Evaluation of multiple biological indicators for the combined diagnosis of metastases from colorectal cancer—a retrospective study based on 1163 patients

Objective This study aimed to investigate the efficacy of inflammatory markers (NLR, PLR) combined with tumor markers (CA50, CA199, CEA) in the diagnosis of colorectal cancer metastasis by a single-center retrospective study.

Methods A total of 1163 CRC patients who received treatments in our hospital from January 2017 to December 2021 were enrolled retrospectively.

Patients were grouped according to the absence of metastasis.

The separate efficacy of tumor markers, NLR and PLR, was evaluated in the diagnosis of metastasis of colorectal cancer using ROC curve analysis, and their optimal cut-off values for distant metastases from colorectal cancer were determined.

The area under the ROC curve (AUC) of the tumor markers combined with NLR and PLR was calculated by binary logistic regression analysis to evaluate the diagnostic efficacy of metastasis of colorectal cancer.

In addition, patients were divided into two groups of high and low levels according to the optimal cut-off values, and the effects of NLR, PLR, and tumor markers on distant metastasis of colorectal cancer were evaluated using multiple logistic regression analysis.

Result The abnormal rate of CA50, CA199, CEA, NLR, and PLR in two subgroupsIt was statistically significant ( P < 0.05).

After AUC testifying, the diagnostic efficacy of NLR and PLR was equivalent to that of tumor marker ( P > 0.05).

In assessment of liver metastasis, peritoneal metastasis, and multiple metastasis, AUC of NLR and PLR with CRC-specific tumor markers showed higher predictive efficacy than AUC without combined NLR nor PLR.

The CA50, CA199, CEA, PLR, and NLR were proved independently associated with metastasis using multiple logistic regression analysis ( P < 0.05).

Conclusion NLR and PLR are noted tumor markers of colorectal cancer, which are characterized by noninvasive, high diagnostic efficacy, easy availability, and low cost.

They can be combined with traditional tumor markers to evaluate and diagnose colorectal cancer metastasis by clinicians.